A Comparative Analysis Between Antibiotic- and Nonantibiotic-Associated Delayed Cutaneous Adverse Drug Reactions.

[1]  S. Silva,et al.  Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). , 2016, Revista da Associacao Medica Brasileira.

[2]  A. Cheng,et al.  The prevalence and impact of antimicrobial allergies and adverse drug reactions at an Australian tertiary centre , 2015, BMC Infectious Diseases.

[3]  S. Mallal,et al.  Abacavir-Reactive Memory T Cells Are Present in Drug Naïve Individuals , 2015, PloS one.

[4]  Chen Wee Derrick Aw,et al.  Severe cutaneous adverse reactions in a local hospital setting: a 5‐year retrospective study , 2014, International journal of dermatology.

[5]  S. Mallal,et al.  HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity , 2014, AIDS.

[6]  C. Chiu,et al.  Severe cutaneous adverse reactions related to systemic antibiotics. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  A. Barbaud.  Skin Testing and Patch Testing in Non-IgE-Mediated Drug Allergy , 2014, Current Allergy and Asthma Reports.

[8]  A. Romano,et al.  Absence of cross‐reactivity to carbapenems in patients with delayed hypersensitivity to penicillins , 2013, Allergy.

[9]  L. Naldi,et al.  Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study , 2013, The British journal of dermatology.

[10]  L. Naldi,et al.  Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2013, The Journal of investigative dermatology.

[11]  B. Milpied,et al.  A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions , 2013, The British journal of dermatology.

[12]  D. Schadendorf,et al.  Detection of abacavir hypersensitivity by ELISpot method. , 2012, Inflammation & allergy drug targets.

[13]  M. Mockenhaupt.  The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis , 2011, Expert review of clinical immunology.

[14]  B. Thong,et al.  Epidemiology and risk factors for drug allergy. , 2011, British journal of clinical pharmacology.

[15]  D. Heckerman,et al.  High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection , 2011, Immunology and cell biology.

[16]  A. Dunant,et al.  ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis , 2010, Clinical pharmacology and therapeutics.

[17]  John A Kellum,et al.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.

[18]  M. Falagas,et al.  The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. , 2006, Journal of medical microbiology.

[19]  J. P. Rife,et al.  Sulfonamide Cross-Reactivity: Fact or Fiction? , 2005, The Annals of pharmacotherapy.

[20]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[21]  L. Naldi,et al.  Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. , 1999, British journal of clinical pharmacology.

[22]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.

[23]  L. Naldi,et al.  Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. , 2008, Journal of the American Academy of Dermatology.

[24]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[25]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[26]  International drug monitoring: the role of national centres. Report of a WHO meeting. , 1972, World Health Organization technical report series.